andyworks / iStockphoto.com
In the current IP landscape it is wise to be prepared for attacks on important patents, as Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, explains to LSIPR.
According to Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, the company is always prepared to combat a patent attack. Since the introduction of the inter partes review (IPR) system in the US, the company has had to reconsider its approach to protecting its innovations because, in its opinion, the IPR is weakening the patent system.
“Although the IPR is a new mechanism, the statistics already show that the likelihood of surviving an IPR is surprisingly low,” says Kellberg.
“This is especially surprising when you take into consideration that the US Patent and Trademark Office (USPTO) has carried out a thorough examination of the patent.”
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
LSIPR 50 2017, Lars Kellberg, Novo Nordisk, inter partes review, IPR, US Patent and Trademark Office,